<DOC>
	<DOCNO>NCT01467427</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The aim trial evaluate safety , efficacy pharmacokinetics ( exposure trial drug body ) NNC-0156-0000-0009 ( nonacog beta pegol , N9-GP ) previously treat child Haemophilia B .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics NNC-0156-0000-0009 Previously Treated Children With Haemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Male patient moderately severe severe congenital haemophilia B Factor IX activity level equal 2 % accord medical record Age equal 12 year ( patient turn 13 year , time inclusion ) Body weight equal 10 kg History least 50 exposure day ( EDs ) FIX product The patient and/or parent ( ) /caregiver capable assess bleed episode , keep electronic diary ( eDiary ) , capable conduct home treatment otherwise able follow trial procedure Known history FIX inhibitor Current FIX inhibitor equal 0.6 Bethesda Units ( BU ) Congenital acquire coagulation disorder haemophilia B Platelet count 50,000/mcL screen Alanine aminotransferase ( ALT ) 3 time upper limit normal reference range screen Creatinine level equal 1.5 time upper normal limit normal reference range screen Human immunodeficiency virus ( HIV ) positive , define medical record , CD4+ lymphocyte count equal 200/mcL Immune modulate chemotherapeutic medication ( except single pulse treatment , inhaled topical steroid ) Previous arterial thrombotic event ( myocardial infarction intracranial thrombosis , define medical record )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>